-transparent.png){kind=logo}
The highly potent and selective anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA] was found to inhibit in vitro the replication of a number of clinical varicella-zoster virus strains within the concentration range of 0.63-5.7 ng/ml. With a mean 50% inhibitory concentration of 1.8 ng/ml and selectivity index of 29000, (S)-HPMPA is one of the most potent and most selective varicella-zoster virus inhibitors discovered to date.
Related Publications
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
January 1987,
Nucleic acids symposium series,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
April 1996,
Tropical medicine & international health : TM & IH,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
May 1998,
Antimicrobial agents and chemotherapy,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
July 1988,
Biochemical and biophysical research communications,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
February 1987,
Antimicrobial agents and chemotherapy,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
February 1998,
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
December 2003,
Antimicrobial agents and chemotherapy,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
October 1987,
Molecular pharmacology,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
February 1996,
Biochemical and biophysical research communications,
M Baba, and
K Konno, and
S Shigeta, and
E De Clercq
November 2007,
Antimicrobial agents and chemotherapy,
